The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 27, 2016

Filed:

Oct. 25, 2012
Applicant:

Ajou University Industry-academic Cooperation Foundation, Gyeonggi-do, KR;

Inventors:

Won Hee Suh, Gyeonggi-do, KR;

Ji Yeon Kim, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61K 31/713 (2006.01); G01N 33/68 (2006.01); C12N 15/115 (2010.01); C07K 16/28 (2006.01); C07K 16/24 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/115 (2013.01); A61K 31/713 (2013.01); A61K 38/17 (2013.01); A61K 38/18 (2013.01); C07K 16/24 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12N 15/1136 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/16 (2013.01); G01N 2333/52 (2013.01); G01N 2333/715 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01); G01N 2800/7057 (2013.01);
Abstract

The present invention relates to a composition comprising a material for inhibiting stem cell factor (SCF) or the receptor thereof for treating or preventing vascular permeability related diseases. Also, the present invention relates to a method for screening for an agent for treating vascular permeability related diseases, comprising the steps of: (a) treating a sample from a patient suspected of having a disease associated with vascular permeability with a candidate material; and (b) comparing the level of expression of the SCF or the receptor thereof with that of a control group. The present invention verifies SCF as a novel target for regulating vascular permeability. When the present invention is used, vascular permeability is decreased in diseases of the eye involving increased vascular permeability, thereby effectively treating or preventing vascular permeability related diseases. Also, vascular permeability can be effectively regulated using the composition. Further, the present invention can be provided as an effective means for screening an agent for treating vascular permeability related diseases by measuring the regulation of the expressions of SCF and c-Kit.


Find Patent Forward Citations

Loading…